Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 93

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 93
---
7 million, and average CAP to our other named executive officers (excluding our PEO) similarly decreased by 80%, from approximately $6.5 million to approximately $1.3 million. TSR increased from $430 to $432 (representing an increase of <1%), and net losses increased by approximately 81%, from approximately $215.3 million to approximately $389.0 million. |

| • | From 2022 to 2023, CAP to our PEO increased by 138%, from approximately $8.7 million to approximately $20.7 million, and average CAP to our other named executive officers (excluding our PEO) similarly increased by 387%, from approximately $1.3 million to approximately $6.4 million. TSR increased from $432 to $787 (representing an increase of 82%) and net losses increased by approximately 34%, from approximately $389.0 million to approximately $522.7 million. |

| • | In 2024, CAP to our PEO was approximately $(1.7) million, which represents a 108% decrease as compared to his CAP of approximately $20.7 million in 2023. The average CAP to our other named executive officers (excluding our PEO) decreased from approximately $6.4 million to approximately $0.6 million, reflecting a 91% decrease year-over-year. TSR decreased from $787 in 2023 to $443 in 2024 (representing a decrease of 44%) and net losses increased 12%, from approximately $522.7 million in 2023 to approximately $587.1 million in 2024. |

For additional context along with a review of our performance metrics, our process for setting executive compensation, and how our executive compensation design reinforces our compensation philosophy, please see the “Compensation Discussion and Analysis” section of this Proxy Statement. All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference into any filing of the Company under the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.

| Cytokinetics, Inc.|2025 Proxy Statement |     | 65 |

TABLE OF CONTENTS

Equity Compensation Plans at December 31, 2024 The following table provides certain information with respect to all our equity compensation plans at December 31,